Bio-Rad Laboratories, Inc. BIO
374.50 USD -11.50 (-2.98%)
Nov 12, 2026, 12:42 PM EST
372.47 Day range 389.98
236.73 52-week range 396.23
- YTD
- +23.60%
- 1 year
- +14.43%
Benzinga news
benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $440 RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $390 to $440.
benzinga.com Bio-Rad Laboratories Q3 2026 Earnings Call Transcript Bio-Rad Laboratories (NYSE:BIO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Bio-Rad Laboratories Affirms FY2026 Sales Guidance of $2.506B-$2.596B vs $2.588B Est Bio-Rad Laboratories (NYSE:BIO) affirms FY2026 sales outlook from $2.506 billion-$2.596 billion to $2.506 billion-$2.596 billion vs $2.588 billion estimate.
benzinga.com Bio-Rad Laboratories Q3 Adj. EPS $2.65 Beats $2.23 Estimate, Sales $656.400M Beat $649.950M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.65 per share which beat the analyst consensus estimate of $2.23 by 18.83 percent. This is a 17.26 percent increase over earnings of…
benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390 RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $370 to $390.
benzinga.com Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330 Citigroup analyst Daniel Grosslight maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from $300 to $330.- benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370 RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $320 to $370.
- benzinga.com Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330 Wells Fargo analyst Evan Stampler maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $310 to $330.
- benzinga.com Bio-Rad Laboratories Lowers FY2026 Sales Guidance of $2.506B-$2.596B vs $2.567B Est Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.506 billion-$2.596 billion to $2.506 billion-$2.596 billion vs $2.567 billion estimate.
benzinga.com Bio-Rad Laboratories Q2 Adj. EPS $2.62 Beats $1.75 Estimate, Sales $651.000M Beat $623.989M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.62 per share which beat the analyst consensus estimate of $1.75 by 49.71 percent. This is a 0.38 percent increase over earnings of…
benzinga.com Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family voting control could pose a hurdle.
benzinga.com Nasdaq 100 Drops Over 1%, Oil Tops $106 On Iran Impasse: Stock Market Today Nasdaq sinks 1.1% as AMAT, MU, ORCL and Vertiv crater on AI capex jitters, while WTI tops $106 and the 10-year yield hovers near 4.6% on stalled US-Iran talks.
benzinga.com Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HIVE, TE, AUTL, GENI, BRC, BIO, BL, RBLX, ZETA, and D.- benzinga.com 'Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad' - WSJ https://www.wsj.com/business/deals/activist-elliott-builds-big-stake-in-life-science-tools-supplier-bio-rad-c99b23fa
benzinga.com RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and announces $320 price target.
benzinga.com Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU U.S. stocks hit fresh records as Apple's blowout Q2 powered Big Tech, while crude oil sank 3% on Hormuz news and Trump set 25% EU auto tariffs.- benzinga.com Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290 Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and lowers the price target from $320 to $290.
- benzinga.com Bio-Rad Laboratories Lowers FY2026 Sales Guidance from $2.596B-$2.622B to $2.506B-$2.596B vs $2.630B Est Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.596 billion-$2.622 billion to $2.506 billion-$2.596 billion vs $2.630 billion estimate.
benzinga.com Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call - benzinga.com Bio-Rad Laboratories Q1 Adj. EPS $1.89 Misses $1.98 Estimate, Sales $592.100M Beat $588.875M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $1.89 per share which missed the analyst consensus estimate of $1.98 by 4.55 percent. This is a 25.59 percent decrease over earnings of…
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com Citigroup Downgrades Bio-Rad Laboratories to Neutral, Lowers Price Target to $300 Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price target from $375 to $300.
benzinga.com Pinterest Posts Downbeat Results, Joins DraftKings, Toast, Expedia And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Bio-Rad Laboratories Sees FY2026 Sales $2.596B-$2.622B vs $2.630B Est Full-Year 2026 Financial OutlookBio-Rad is providing its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency neutral revenue growth of approximately 0.5 to 1.5…
benzinga.com Earnings Summary: Bio-Rad Laboratories Q4 
benzinga.com Bio-Rad Laboratories Q4 Adj. EPS $2.51 Misses $2.70 Estimate, Sales $693.200M Beat $688.758M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.51 per share which missed the analyst consensus estimate of $2.70 by 7.04 percent. This is a 13.45 percent decrease over earnings of…- benzinga.com Earnings Scheduled For February 12, 2026
benzinga.com Qiagen Explores Possible Sale After New Buyer Talks: Report Qiagen is reviewing strategic options, including a potential sale, after renewed takeover interest from several buyers.- benzinga.com Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375 Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and raises the price target from $350 to $375.
- benzinga.com Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $340 Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $265 to $340.
benzinga.com CORRECTION: Bio-Rad Laboratories Q3 Adj. EPS $2.26 Beats $1.93 Estimate, Sales $653.000M Beat $651.301M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.26 per share which beat the analyst consensus estimate of $1.93 by 16.92 percent. This is a 11.88 percent increase over earnings of…- benzinga.com Bio-Rad Laboratories Affirms FY2025 Sales Guidance of $2.567B-$2.593B vs $2.593B Est Full-Year 2025 Financial OutlookBio-Rad is maintaining its financial outlook for the full year 2025. The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 0 to…
benzinga.com Earnings Scheduled For October 29, 2025 
benzinga.com Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings - benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $409 RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $387 to $409.
benzinga.com Monolithic Power Systems, Workiva, Interface, AppFolio And Other Big Stocks Moving Higher On Friday 
benzinga.com Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $265 Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $245 to $265.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Bio-Rad Laboratories Narrows FY2025 Sales Guidance from $2.541B-$2.606B to $2.567B-$2.593B vs $2.520B Est Bio-Rad Laboratories (NYSE:BIO) narrows FY2025 sales outlook from $2.541 billion-$2.606 billion to $2.567 billion-$2.593 billion vs $2.520 billion estimate.
- benzinga.com Bio-Rad Laboratories Q2 Adj. EPS $2.61 Beats $1.76 Estimate, Sales $651.600M Beat $615.110M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.61 per share which beat the analyst consensus estimate of $1.76 by 48.63 percent. This is a 16.08 percent decrease over earnings of…
- benzinga.com Earnings Scheduled For July 31, 2025
- benzinga.com 5 Analysts Have This To Say About Bio-Rad Laboratories
- benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session
- benzinga.com UBS Maintains Buy on Bio-Rad Laboratories, Lowers Price Target to $310 UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and lowers the price target from $355 to $310.
- benzinga.com Citigroup Maintains Buy on Bio-Rad Laboratories, Lowers Price Target to $350 Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and lowers the price target from $400 to $350.
- benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Lowers Price Target to $392 RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and lowers the price target from $409 to $392.
- benzinga.com Bio-Rad Laboratories Q1 Adj. EPS $2.54 Beats $1.81 Estimate, Sales $585.40M Beat $573.26M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.54 per share which beat the analyst consensus estimate of $1.81 by 40.33 percent. This is a 10.92 percent increase over earnings of…
- benzinga.com Earnings Scheduled For May 1, 2025
- benzinga.com A Preview Of Bio-Rad Laboratories's Earnings